Table 3.

Effect of the DA D₂ receptor agonist quinpirole of α PSP summation when protein kinases are inhibited

Drug	Condition	αPSP summation
		−70 mV	−55 mV
GF109203X (10 μm) (n = 4)	Baseline	1.50 ± 0.09	2.37 ± 0.27
	Quinpirole	1.46 ± 0.17	2.40 ± 0.17
KT5720 (1 μm) (n = 8)	Baseline	1.56 ± 0.05	2.22 ± 0.22
	Quinpirole	1.64 ± 0.08	2.55 ± 0.15*
Chelerythrine (2 μm) (n = 7)	Baseline	1.59 ± 0.06	2.31 ± 0.15
	Chelerythrine	1.58 ± 0.06	2.97 ± 0.23*
	Quinpirole	1.59 ± 0.05	2.27 ± 0.17*
TTX (0.5 μm) + chelerythrine (2 μm) (n = 5)	TTX	1.49 ± 0.20	1.50 ± 0.16
	+Chelerythrine	1.47 ± 0.06	1.32 ± 0.14
U73122 (3 μm) (n = 6)	Baseline	1.38 ± 0.07	2.13 ± 0.16
	U73122	1.37 ± 0.10	2.16 ± 0.22
	Quinpirole	1.36 ± 0.07	2.20 ± 0.24
BAPTA (20 mm) (n = 6)	Baseline	1.39 ± 0.08	2.09 ± 0.18
	Quinpirole	1.34 ± 0.04	2.28 ± 0.16
Cyclosporin A (1 μm) (n = 5)	Baseline	1.41 ± 0.14	2.42 ± 0.20
	Cyclosporin A	1.36 ± 0.15	1.96 ± 0.21*
	Quinpirole	1.36 ± 0.11	1.88 ± 0.17
Calcineurin autoinhibitory peptide (100 μm) (n = 6)	Baseline	1.21 ± 0.09	1.14 ± 0.07
	Quinpirole	1.68 ± 0.18	1.61 ± 0.16
Okadaic acid (100 nm) (n = 6)	Baseline	1.70 ± 0.15	2.26 ± 0.15
	Okadaic acid	1.61 ± 0.14	2.02 ± 0.14
	Quinpirole	1.52 ± 0.15	1.96 ± 0.21
SQ22536 (100 μm) (n = 5)	Baseline	1.68 ± 0.10	2.15 ± 0.17
	Quinpirole	1.77 ± 0.13	2.41 ± 0.20*
Forskolin (5 μm) (n = 5)	Baseline	1.57 ± 0.13	2.14 ± 0.13
	Forskolin	1.50 ± 0.08	1.81 ± 0.08*
Forskolin (25 μm) (n = 6)	Baseline	1.55 ± 0.09	2.31 ± 0.14
	Forskolin	1.42 ± 0.09	1.99 ± 0.13*
	Quinpirole	1.48 ± 0.10	2.38 ± 0.15*

Quinpirole was applied at 10 μm. BAPTA, calcineurin autoinhibitory peptide, and SQ22536 were all applied intracellularly. *p < 0.05, significant difference with paired t test compared with baseline (or previous) condition at the same V_m.